内皮抑素是一种强有力的内源性血管生成抑制因子。它抑制血管内皮细胞的增生,迁移,且无毒性、无耐药性。内皮抑素在体外不稳定,需长期大剂量用药,如何提高内皮抑素生物活性是当今一个热门话题。内皮抑素可以通过化学共价修饰或基因突变改变其结构,提高其稳定性与抑制新生血管活性。我们旨在探讨改良内皮抑素与眼部新生血管的研究进展,并讨论改良内皮抑素的优越性。研究改良内皮抑素也有助于我们了解内皮抑素作用的分子机制.改良内皮抑素有望作为一种新的血管生成抑制剂应用于临床,从而取代内皮抑素。 Endostatin is a potent endogenous angiogenesis inhibitor. It inhibits the proliferation of vascular endothelial cells, migration, and non-toxic, non-drug-resistant. Endostatin instability in vitro, long-term high-dose medication, how to improve the biological activity of endostatin is a hot topic today. Endostatin can change its structure through chemical covalent modification or gene mutation, improve its stability and inhibit neovascularization activity. We aimed to explore the improvement of endostatin and ocular neovascularization research progress, and discuss the advantages of modified endostatin. The study of modified endostatin also helps us to understand the molecular mechanism of endostatin.It is expected that endostatin will be used as a new angiogenesis inhibitor in clinic to replace endostatin.